Trial Profile
Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 09 Sep 2016 New trial record